Thank you for donating!

You can donate using the following services.

Urgent: The Data Protection Law has Changed!

Due to changes in data protection legislation, NPUK won’t be able to contact you about any of our services or activities unless you explicitly give your consent - in short if you want to continue to receive our service, we need to get your direct permission. More information can be found below in 'Latest News'

NPUK 25th Annual Family Conference & Interactive Workshop

Thank you to everyone who attended September's Annual Family Conference and Interactive Workshop - particularly those working on the Children & Young Person's Activity Programme! We hope everyone had a positive experience, and hope to see you all soon.

New NPUK YouTube content coming soon!

Please subscribe to our YouTube channel @NiemannPickUK to never miss an upload - new content, shot by CineBites' fantastically talented Carl Mason over the Conference weekend is on its way very soon!

Explore NPUK

View all

Latest news

15.03.19

CTD Holdings Announces Plan to Launch Clinical Trial of Trappsol® Cyclo™ in Alzheimer’s Disease

ALACHUA, FL – (Globe Newswire) – March 14, 2019 – CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that the company has initiated planning for a Phase I clinical trial for treatment of Alzheimer’s Disease. The trial will use Trappsol® Cyclo™, the company’s proprietary formulation of hydroxypropyl beta cyclodextrin, administered intravenously.

Read more

11.03.19

IntraBio Clinical Trial Authorization Application Approved by the MHRA for the Treatment of Niemann-Pick Disease type C (NPC)

IntraBio Clinical Trial Authorization Application Approved by the MHRA for the Treatment of Niemann-Pick Disease type C (NPC): OXFORD, UK, March 11, 2019-- IntraBio Inc., a late-stage biopharmaceutical company, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved its Clinical Trial Authorisation (CTA) Application for Clinical Trial IB1001-201 with its lead compound (IB1001) for the treatment of Niemann-Pick disease Type C (NPC).

Read more
View all news Subscribe